21 January 2021 - In 2019, the Canadian Drug Insurance Pooling Corporation's (CDIPC) high-cost drug sharing framework provided coverage to 27,000 Canadians whose annual drug costs exceed $10,000, an increase of 17% over 2018.

Measured as a percentage of overall drug benefits paid by insurers, high-cost drugs (including rare disease drugs) associated with EP3-based insurance plans accounted for less than two per cent of claimants but grew from 35% to 42% of costs in three years leading up to 2019.

Read Canadian Drug Insurance Pooling Corporation press release